May 2, 2013 - LifeVest Wearable Defibrillator, Advanced Resuscitation Technology, and Temperature Management Solutions To Be Showcased at Heart Rhythm


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
[email protected]  




May 2, 2013—CHELMSFORD, MASS.—ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will display its portfolio of clinical resuscitation products including the LifeVest® Wearable Defibrillator, along with sudden cardiac death (SCD) education and screening tools, in Booth #539 at Heart Rhythm 2013, the Heart Rhythm Society’s 34th Annual Scientific Sessions, May 8-11 at the Colorado Convention Center in Denver.

The LifeVest will be discussed during the following scientific sessions:

  • Late Breaking Clinical Trials: Ilan Goldenberg, MD, University of Rochester Medical Center, will present “Eighteen Month Results From The Prospective Registry And Follow-up Of Patients Using The LifeVest Wearable Defibrillator (WEARIT-II Registry)” during the Late Breaking Clinical Trials II, Friday, May 10, 1:30-3:00 p.m., Four Seasons Ballroom 1, Session number SP22.
  • Johannes K. Sperzel, MD, Kerckhoff Heart Center, will present “Role of the Defibrillator Vest as Bridging Therapy before ICD (Implantable Cardioverter Defibrillator) Implantation,” Friday, May 10, 1:45-2:00 p.m., Mile High Room 1A, Abstract number AB32-02.
  • Michael J. Mirro, MD, Indiana University School of Medicine, will present “The use of Wearable Cardioverter Defibrillator among high risk cardiac patients,” Thursday, May 9, 6:00-7:30 p.m., Exhibit Hall, Poster number PO01-42.

LifeVest Provides Protection for Patients at Risk of SCD

The LifeVest protects patients at risk for SCD. It is used to protect a wide range of patients, including patients with newly diagnosed heart failure, following recent myocardial infarction, or following coronary revascularization. Following a percutaneous coronary intervention (PCI), procedure, 1 in 5 patients have been shown to be at high risk of early mortality.i In post-PCI patients with a low ejection fraction (≤35%), 3 month mortality is 13%,ii and increases significantly in the presence of other risk factors.iii The LifeVest provides protection during this period of high risk, gives physicians time to optimize medical therapy, and helps ensure patients are not lost to follow up.

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.

Additional products on display from ZOLL include:

  • The AutoPulse® Non-Invasive Support Pump is an automated, portable chest compression device. It is the only mechanical CPR system to have shown improved human survival in comparative clinical trials. The AutoPulse more than tripled survival compared to typical CPR during witnessed shockable arrests.iv 
  • The R Series® Code-Ready Defibrillators are designed to extend “Simple, Smart and Ready” defibrillation to every hospital department through advanced, cost-effective solutions for resuscitation. The original R Series ALS, and the newer R Series Plus, which has both AED and ALS capabilities at the touch of a button, offer See-Thru CPR®, a breakthrough technology that filters out CPR artifact from the ECG to reduce CPR interruptions. Like all ZOLL defibrillators, the R Series also features RealCPR Help® audio and visual feedback for the correct depth and rate of chest compressions.
  • Intravascular Temperature Management (IVTM™) technology offers health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. The Thermogard XP® delivers accurate, easy-to-use and cost-effective control for both cooling and warming applications.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. For more information, visit

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 25,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit

Copyright © 2013 ZOLL Medical Corporation. All rights reserved. AutoPulse, Code-Ready, IVTM, LifeVest, Real CPR Help, R Series, See-Thru CPR, Thermogard , and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All trademarks are the property of their respective owners.

i Halkin, A et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: CADILLAC Risk Score. JACC 2005;45:1397–1405.
ii Zishiri E, et al. Use of the Wearable Cardioverter Defibrillator and Survival After Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction. Circulation 2011; 124:A9816.
iii Weintraub et al. Prediction of Long-Term Mortality After Percutaneous Coronary Intervention in Older Adults: Results From the National Cardiovascular Data Registry. Circulation 2012;125:1501–1510.
iv Wik L, et al. The impact of CPR duration on survival to discharge between integrated AutoPulse-CPR and manual–CPR during out-of-hospital cardiac arrest of presumed cardiac origin. Resuscitation. 2012;83:e17